Wed, 18 April 2018
Alkermes’ ALKS-5461 gets a do-over, Celldex's lead drug is a bust, and the good and bad of Johnson & Johnson's Q1 earnings report. Thanks to Blooom for supporting Industry Focus. Get a month free with blooom401k.com/fool and code fool. |